$AVIR
Atea Pharmaceuticals Inc
PRICE
$4.215 ▼-1.288%
Extented Hours
VOLUME
355,878
DAY RANGE
4.27 - 4.55
52 WEEK
2.94 - 9.79
Key Metrics
Market Cap
379.47 M
Beta
1.21
Avg. Volume
1.26 M
Shares Outstanding
83.40 M
Yield
0%
Public Float
0
Next Earnings Date
2023-08-08
Next Dividend Date
Company Information
atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.
Website: ateapharma.com
HQ: ,
Related News